The new FDA count for compounded semaglutide adverse events is serious, but it is easy to read it the wrong way. Compounding means a pharmacy prepares a medication for an individual prescription. Semaglutide is a GLP-1 medicine, a drug that mimics a gut hormone involved in appetite and blood sugar. The agency has received 990 reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. Those numbers are reports, not proof that a compounded drug caused every event, and they do not tell us the chance that one patient will have a problem. The clearest preventable pattern in the FDA record is simpler: people, and sometimes clinicians, have made dosing errors when converting between milligrams, milliliters, and syringe units.
What the FDA update says about compounded semaglutide adverse events
As of September 18, 2026, the day this article was written, the FDA's current GLP-1 page carries the line "Content current as of: 09/01/2026." It says that, through May 31, 2026, the agency had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.
An adverse event is a health problem reported after a medicine was used. It is a signal for investigators, not a finding that the medicine caused the problem. FDA says many reported events resemble effects already seen with the approved versions, and that other factors may have contributed.
The page also says the count is probably incomplete. Many state-licensed pharmacies that prepare individual prescriptions are not federally required to send adverse-event reports to FDA. That leaves a real reporting gap, but it does not turn the reports FDA has into a rate. There is no reliable denominator here—the number of people who used each compounded formulation, meaning the particular preparation dispensed—so 990 cannot be converted into "one person in X."
The FDA's drug-alert index dates the underlying item to February 4, 2026. The fresh September record is the September 1 revision to that existing page, not a separate FDA press release. That distinction matters because the substance is a refreshed count and a broader set of concerns, not a newly announced finding that every compounded GLP-1 has the same problem.
Why the report count cannot answer "how risky is it?"
A report can be filed because a drug is suspected, even when the cause is uncertain. Reporting also changes with publicity, how long a product has been used, and whether the pharmacy has a federal duty to report. None of that makes the reports unimportant. It means the right question is what pattern they reveal.
The best-supported pattern is medication error. In a 2025 review of 1,047 calls to California poison centers, 36 involved compounded GLP-1 medicines and 33 of those 36 involved administration errors (Ho and colleagues, Journal of Pharmacy Technology, 2025). That small subgroup cannot establish a national rate, but it shows where a preventable risk can enter.
The ordinary side-effect picture belongs in the separate guide to semaglutide side effects. The FDA count answers a different question: what problems are reaching the agency from compounded products, and what about the way those products are prescribed, labeled, measured, and reported may need attention.
How compounded GLP-1 dosing errors happen
A milligram is the amount of drug. A milliliter is the volume of liquid. Concentration is the amount of drug in each milliliter. A syringe "unit" is a volume mark, and it does not identify a milligram dose unless the vial's concentration is known. If the concentration changes, the same number of units can represent a different amount of medicine.
In its detailed compounded semaglutide dosing-error alert, FDA described people receiving five to 20 times the intended amount. Some patients needed medical care or hospitalization. The agency traced errors both to patients drawing the wrong volume and to clinicians miscalculating the conversion.
A three-person poison-center case series gives that warning a human scale. Two people administered ten times the intended amount; all three reported nausea, vomiting, and abdominal pain, and one person said the directions were expressed in milliliters and units rather than milligrams (Lambson and colleagues, Journal of the American Pharmacists Association, 2023). Three cases cannot show frequency, but they show how a unit conversion becomes a medical event.
The companion guide to compounded tirzepatide side effects explains the same two-layer problem: the molecule has known effects, while concentration, syringe markings, additives, and preparation quality can introduce separate questions.
What a prescribed, pharmacy-labeled route changes
It does not make side effects disappear. It gives the dose a chain of accountability. A prescriber sets the dose in milligrams. The dispensing label ties the drug amount to the liquid volume and concentration. A pharmacist can answer a measurement question before the injection, and the prescription, lot, and patient are connected if something goes wrong.
That label detail is not cosmetic. FDA's injectable-label guidance recommends showing the amount per total volume prominently, with the amount per milliliter close by. The point is to make the intended amount and the volume used to measure it hard to confuse.
A grey-market vial sold without a prescription may offer none of that: no clinician who chose the dose, no identified dispensing pharmacy, and no clear route for tracing a lot or reporting a problem. The good version of compounded care is not merely "a vial from a pharmacy." It is a specific prescription, a readable label, counseling that matches the syringe and concentration, and reachable people on both sides of the dispensing step.
At Promise, a licensed provider reviews every request, and not everyone qualifies. A licensed provider may still prescribe a compounded formulation when it is appropriate and lawful; that decision is between the patient and the doctor.
Through Promise, semaglutide and tirzepatide are dispensed as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved. The September count does not change that distinction, and regulatory status is not a substitute for an individual prescribing decision.
What the FDA update does not mean
It does not mean 990 people were proved to have been harmed by compounded semaglutide. It does not show that compounded semaglutide is 990 times riskier than anything else. It does not separate an expected drug effect from an excessive dose, a labeling problem, a product-quality problem, or an unrelated illness in every case.
It also does not make a familiar symptom unimportant. A reaction can look like a known GLP-1 effect and still be unusually severe because the measured amount was wrong. The useful questions are concrete: what dose in milligrams was prescribed, what concentration was dispensed, what volume did the label connect to that dose, and was the syringe the one the directions described? Those are questions for the prescriber and dispensing pharmacist, not a conversion to reconstruct from an online chart.
What to watch next
The next useful FDA update will be one that adds context to the counts: newer reporting dates, clearer categories for medication errors and product-quality problems, or better reporting from state-licensed pharmacies. Until then, the current figures are a warning signal, not a risk calculator.
FDA accepts suspected side effects, medication errors, and quality problems through MedWatch, the agency's safety-reporting program. Consumers can use Form 3500B even when they are not certain what caused the event. The practical sequence and the details worth recording are covered in how to report peptide side effects.
